Prolonged Disease Control on Tepotinib in a Patient with HLA-DRB1-MET-positive Metastatic Non-Small Cell Lung Cancer: The Role of RNA Sequencing and Targeted Therapy for Rare MET Rearrangements

The MET gene encodes a receptor tyrosine kinase that plays a crucial role in cellular signaling pathways.1 MET alterations found in non-small cell lung cancer (NSCLC) include gene amplification and exon 14 skipping mutations, the latter of which occur in 2-4% of treatment-naïve cases.2-5 MET exon 14 skipping mutations are most commonly found in adenocarcinoma and sarcomatoid histologies, and they represent a targetable driver alteration for tyrosine kinase inhibitors (TKIs) such as tepotinib and capmatinib.